

Index

- Abelson, J., 254–255
- Academia Platonica* (Neoplatonic Florentine Academy), 218
- Academy of Medical Sciences (AMS, UK), 358–359
goals and mission of, 3–5
- access to healthcare
benefit sharing and, 154–156
orphan drug research and, 62
solidarity and, 59–61
- accountability
governance and, 123–124
institutional decision-making and, 211
medical device failure and, 163–164
non-traditional medicine and, 299
- actor-networks
Big Data research and, 257–259
global health emergency guidelines and, 316–317
- adaptive governance principles
Big Data research and, 257–265
evolution of, 257–259
structures and processes in, 263–265
visibility, 264–265
- adaptivity, in health research governance, 259–260
- Addgene company, 142–144
- Additional Protocol (2005), 105–106
- add-on services in reproductive medicine
ethical issues with, 375–377
patient choice dynamic in, 380
regulation of, 377–379
risks of, 380–381
- advanced therapies
Argentinian regulation of, 324–331
regenerative medicine and, 324
- advertising of innovative intervention, oversight of, 292–295
- Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
- advisory committees
adaptive governance and, 263–265
Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
in bioethics, 220–222
- Bioethics Advisory Body, 284–285
future of health research regulation and, 222–224
health policy advice and, 215–216
advocates, public engagement with, 117
- affected public
classification of, 117
data-intensive health research and, 118–119
- AFIRRM oversight model
Big Data research and, 259–260
future challenges for, 265
implementation of, 260–263
- agency, automated healthcare regulation and, 268–269, 273
- aggregated data, individual discrimination and stigmatisation and, 242
- aggregative theories, public interest and, 240
- Aitken, Mhairi, 14, 70–71, 112–129
- Alder Hey organ retention scandal, 212–213
- Aldrick, Philip, 270
- Allen, A. L., 75
- All of Us initiative, 103–104
- All Party Parliamentary Group on Surgical Mesh Implants, 162–165
- alternative medicine
history and evolution of, 296–298
research regulation of, 296–305
uncertainty of knowledges and practices and, 303–304
as *in vitro* add-on, 375–377
- Althusser, L., 251–252
- animal research
embryo research and, 356–364
human material in animals and, 358–359
interspecies research and, 356–364
in neuroscience, 310–312
regulation and oversight of, 359–362
shifting regulatory boundaries in, 362–363
vulnerability issues in regulation of, 363–364
- Animals Containing Human Material* (Academy of Medical Sciences), 358–359
- Annas, George, 352
- Ansell, C., 124–125, 128–129

- anticipatory knowledge
 emerging science and technology oversight and, 397–399
 in global health emergency research, 322–323
 participatory health governance and, 285–286
- anti-science politics
 health policy formation and, 216–218
 health research regulation and, 222
 traditional and non-conventional medicine and, 301–302
- Argentina
 agricultural strength and health fragmentation in, 324–325
 cell therapy research governance in, 325–326
 construction of research governance in, 328–329
 current health legal/regulatory framework in, 330–331
 health research regulation in, 324–331
- Arnstein, S. R., 114, 116
- ArthritisPower network, 126–127
- artificial intelligence (AI)
 best practices guidelines and, 175
 co-dependent human-technology embodiment and, 383–384
 continuous learning, research-therapy divide and, 277–286
 existence conditions and, 272
 as medical device, 277–286
 regulatory responsibility and, 271–274
 voluntariness in, 107–108
- assisted reproduction, human germline research and, 348–350
- Association of University Technology Managers, 142–143
- Australia
 cloning research in, 347–348
 evidence-informed health policy in, 216–218
- Australian Academy of Learned Societies, 220
- authority. *See* governance
- autologous mesenchymal stem cell case study, clinical
 innovation oversight and, 290–292
- automated healthcare regulation
 balance of interests in, 267–268
 moral development and agency and, 273–274
 regulatory responsibility and, 271–274
 self-development and agency issues and, 273
 stewardship responsibilities in, 268–269
- autonomy
 artificial intelligence and, 271
 disclosure of research findings and, 233–234
 health research ethics guidelines, 27–29
 health research regulation and, 13–15
 individualistic conceptions of, 29–30
 informed consent and, 104–105, 108–109
 non-invasive prenatal testing and, 267–268
 privacy and, 246
 relational conceptions of, 27–36
- availability heuristic, risk-benefit analysis and, 134–135
- Aviesan initiative, 103–104
- Baier, A., 84–85
- balance of interests
 automated healthcare regulation and, 272
 health research regulation and, 268
- Ballantyne, A., 23–24
- Barbazza, E., 123–124
- Barber Surgeons of Edinburgh, 218
- Barsdorf, Nicola, 51–52
- Bea, Sara, 356–364
- Beauchamp, T. L., 39, 169–170
- beliefs, facts and, health policy and, 217
- Belmont Report* (1979), 7–8
 autonomy guidelines in, 27–29
 social values, 46–47
 vulnerability guidelines in, 17–18, 33
- beneficence
 autonomy guidelines and, 27–29
 informed consent and, 104–105
 proportionality and, 39
- benefit analysis
 risk-benefit analysis and, 132–134
 social value and, 53–54
- benefit evaluation, social value and, 54
- benefits, defined, 149–151
- benefit sharing
 challenges to, 154–156
 common heritage argument for, 150–151
 data access agreements and, 191
 descriptive argument for, 150–151
 governance frameworks for, 151–153
 health research regulation and, 148–157
 history and rationale for, 149–151
 procedures for, 153–154
- benefit treatment, social value and, 54
- Bennet, C. J., 241–243
- Bennett, Alan, 145–146
- Beresford, P., 121–123
- Berger, M., 251–252
- best practices
 displacement of traditional medicine in, 299–301
 examples, 192–195
 health research regulation, 173–175
in vitro fertilisation and, 374
- Big Data research. *See also* data-driven research
 adaptive governance in regulation of, 257–265
 analytical techniques in, 257–259
 deliberative participatory practices and, 125–126
 effective governance of, 260–263
 participatory governance of research and, 121
 patient and public involvement in, 121–123
 regulatory scholarship on, 257–259
 structures and processes in, 263–265
 systemic oversight framework for, 259–260
 uncertainty in, 262–263
 voluntariness in, 107–108
- biobanks
 disclosure of research findings and role of, 233
 regulation of, 6–7
- Biobricks Foundation, 142–143
- bioethics
 advisory committees, 220–222, 284–285
 French law on, 264
 medical device failure and, 162–165
- Bioethics* (journal), social value debate in, 51–52
- biosecurity regulations, in Argentina, 324–325
- blaming, medical device failure and, 163–164

- Blasimme, Alessandro, 217
- blinded trials, evidence-based medicine and, 298–299
- Blueprint for Dynamic Oversight of Emerging Science and Technologies, 397–399
- bottom-up participation
- participatory health governance and, 124–125
 - principles-based regulation and, 259
- Boyd, Ian, 217
- Bracken-Roche, D., 20–22
- Bradwell, P., 118
- Brandeis, S. D., 75
- Brassington, Iain, 14–15
- Braun, K., 112–113, 117
- Breakthrough Device designation (FDA), 278–281
- Briggs (Lord Justice), 245–246
- bright line ideology, human germline research and, 349–350
- broad consent principle, 103–104
- Broad Institute, 143–146
- Brownsword, Roger, 266–274
- Bryant, R., 159–160
- burdened populations, solidarity in health research for, 59–61
- Burgess, Michael M., 14, 69–70, 248–256
- Bush, George W., 216–218, 222–223
- Caldicott Principles, 167–168
- Caldicott Report, 248–249
- Canada
- autonomy guidelines in, 27–29
 - ethics review in, 200–201
 - genetics research regulation in, 337–340
- Canadian Academy of Engineering, 219–220
- Canadian Academy of Health Sciences, 219–220
- Canadian Tri-Council, 19–20
- capacity perspective
- cooperative tool for capacity building, 153
 - participatory governance and, 127
 - vulnerability and, 24–25
 - in vulnerability research, 20–22
- Care Act 2014 (UK), 182–184
- care.data scheme (UK), 118–119, 122–123, 248–249
- Carroll, T., 159–160
- Carter, P., 69–70
- Categorical Imperative (Kant), 78–79
- cell therapy research, Argentinian governance of, 325–326
- centralised supervision and coordination, participatory governance and, 128–129
- Chambers, Simone, 252–253
- Chan, Sarah, 344–355
- Charities Commission (UK), 301–302
- children, relational autonomy of, 34–36
- Childress, J. F., 39, 169–170
- chimeric organisms
- interspecies research and, 357–358
 - research guidelines involving, 360
 - shifting regulatory boundaries in research on, 362–363
 - vulnerability issues in research on, 363–364
- China, human gene editing in, 337–341, 351, 353
- Chuong, Kim H., 121–129
- circumstances, vulnerability and, 23–24
- citizens
- identity interests in health research regulation and, 397–399
 - public engagement with, 117
- citizens' forums, participatory health systems governance and, 125–126
- clarity of purpose
- participatory governance and, 128
 - public engagement and, 118–119
- clinical decision support (CDS) software
- AI/ML software, 278–281
 - research-therapy divide and, 277–278
- clinical equipoise, component analysis and, 135–136
- clinical research
- innovation in marketplace and, 287–295
 - social value in, 51–52
- ClinicalStudyDataRequest, 192–195
- clinical trials regulatory paradigm
- economics of clinical guidelines and, 301–302
 - evidence-based medicine and, 298–299
 - medical device trials, 279–281
 - pay-to-participate clinical trials and, 290–292
 - regulatory research and, 5–9
 - social value and, 52
 - traditional and alternative medicines and, 299–301
- clinical utility of information, disclosure of research findings based on, 231
- Clinton, Bill, 221–222
- Cloatre, Emilie, 296–305
- cloning
- ethical review of, 221–222, 335–336
 - international health policy frameworks on, 340–341
 - legislation involving, 347–348
 - terminology and definitions of, 347–348
- clustered regularly interspersed palindromic repeats (CRISPR) patents, 143–146
- ethical issues in, 267–268
 - human gene editing regulation, 335–336
 - human germline research and, 345–346
- co-dependent human-technology embodiment
- enhancement innovations and, 383–384
 - identity and integrity issues in, 384–386
- coercive isomorphism, 213
- cognitive bias, risk-benefit analysis and, 134–135
- cognitive disability, relational autonomy and, 34–36
- Colbert, Jean-Baptiste, 218
- Coleman, Carl H., 14, 130–138
- Coleman, S., 119–120
- collaborative licensing, 144–145
- patent regulation and, 144–145
- collaborative research
- Argentinian-University of Edinburgh research governance collaboration, 325–326
 - Big Data research and, 257–259
 - categories of, 82–83
 - clinical innovation oversight and, 289–290
 - data sharing collaborations, trust in, 87–89
 - human germline research, 350–352
 - in interspecies research, 363–364
 - in neuroscience, 308
 - participatory health governance and, 124–125, 285–286
 - patent rights and, 141
 - trust and, 81–82

- collective interests
 - health research regulation and, 7, 14
 - public expertise mobilisation and, 253–255
- commercialisation of research
 - benefit sharing and, 154–156
 - data access and, 192–195
 - group vulnerability and, 97
 - health research regulation and, 7
- common good
 - automated health regulation and, 268–269
 - privacy and, 78
- common heritage argument for benefit sharing, 150–151
- common interest theory
 - group privacy and, 241–243
 - public interest and, 240–241
- Common Rule. *See* Federal Policy for the Protection of Human Subjects (Common Rule, US)
- common value theory, 240–241
- communitarian approach
 - automated health regulation and, 268–269
 - benefit sharing, 153–154
 - global health emergencies and, 319–320
 - informed consent and, 108–109
 - institutional decision-making and, 210
 - risk-benefit analysis and, 138
- community advisory boards, participatory health systems
 - governance and, 125–126
- community values. *See* social value
- Compagnie du Gai Sçavoir*, 218
- comparative effectiveness research, minimal risk principle and, 199–200
- competency
 - autonomy and, 31
 - informed consent and, 106
- competition, patent regulation and, 140–141
- complementarity, governance structures and, 264
- complementary and alternative medicine (CAM). *See* alternative medicine
- component analysis, risk-benefit analysis using, 135–136
- confidentiality
 - in Big Data research, 123
 - duty of confidence and, 245–246
 - in neuroscience research, 308
 - privacy and, 79
 - public interest guidelines and, 67–70
- Confidentiality Advisory Group (CAG) (HRA, UK), 67–70, 212–213
- Confronting the Liminal Spaces of Health Research Regulation project, 3
- consent. *See* informed consent
- consent or anonymise regulation model, 4
- consent to contact policies, 201–202
- consultation, public engagement through, 115–116
- consumerist approach
 - autologous mesenchymal stem cell case, 290–292
 - clinical innovation and intervention and, 289
 - innovation oversight and limits of, 292–295
 - medical device regulation and, 386–389
 - misinformation about reproductive medicine and, 379
 - non-traditional medicine and, 299
 - patient and public involvement and, 121–123
 - in vitro* fertilisation and, 375–377
- consumers, public engagement with, 117
- context
 - in adaptive governance, 262
 - in global health emergency guidelines, 316–317
 - health research regulation and role of, 275–276
 - in human germline research, 348–350
 - of institutions, 207–208
 - proportionality and, 37–38
 - rule-based and practice-based health regulation and, 172–173
- Contreras, Jorge, 141–142
- controlled access, data-driven research, 190–191
- Convention for the Protection of Individuals with regard to Automatic Processing of Personal Data (Council of Europe), 243–245
- Convention on Biological Diversity (CBD) (1992), 149
- cooperative practice, human germline research, 350–352
- cooperative tool for capacity building, benefit sharing and, 153
- co-optation, participatory governance and, 127
- costs of health research, solidarity on, 59–61
- Council for International Organizations of Medical Sciences (CIOMS), 18–20
 - benefit sharing guidelines and, 151–153
 - global health emergency guidelines and, 316–317, 320–322
 - guidelines, 47–49
 - health practices guidelines, 173–175
 - informed consent and, 105–106, 200–201
 - reasonable availability model of, 152–153
 - risk-benefit analysis guidelines, 137
 - social value in health research regulation and, 46–47, 49–51, 199–200
 - on third-party risks, 130–132
- Council of Canadian Academies (CCA), 219–220
- Council of Europe
 - data protection law and, 243–245
 - genetics research regulation and, 340–341
 - informed consent and, 105–106
- Council on Health Research for Development (COHJRED), 85–86
- COVID-19 pandemic
 - health practices guidelines and, 173–175
 - research exceptionalism and, 318–320
- credibility tactics, participatory governance and, 127
- Crick, Bernard, 96
- criminal law
 - genetics research regulation and, 337–340
 - human embryo research and, 358–359
 - physical integrity and identity in, 385–386
- crisis research
 - global health emergency guidelines and, 316–317
 - human gene editing regulation and, 335–336
 - risk assessment in, 199–200
 - social value of, 317–318
- criticism, of research ethics, 200–201
- cross-border data sharing, in Big Data research, 123

- cultural issues
 disclosure of research findings and, 233–234
 interspecies biomedical research regulations and, 362–363
 medical device failure and, 163–164
 privacy and, 241–243
- culturally significant information, protection of, 242n.23
- Cunningham-Burley, Sarah, 14, 112–129
- Curran, William, 181–182
- cyborg perspective, enhancement innovations and, 383
- D'Amour, D., 83
- data access
 agreements, 191
 centralised access, genotype/phenotype database, 193
 challenges and future directions, 195–196
 governance of, 187–196
 harmonisation of policies and processes in, 196
 independent, interdisciplinary access, 193–194
 multi-study access, EGA, 192
 oversight coordination, 195–196
 producers' rights and interests and, 194
 resources, effectiveness and efficiency in, 195
 tiered access, International Cancer Genome Consortium/25K Initiative, 193
 transparency and reflexive governance, 194–195
- Data Access Committees (DACs), 188–189
 adaptive governance and, 263–265
 controlled vs. open access data and, 190–191
 monitoring of data use and, 191–192
 multi-study access, EGA, 192
 oversight coordination, 195–196
 resources, effectiveness and efficiency in, 195
- data-driven research. *See also* Big Data research
 automated healthcare regulation and, 270
 controlled vs. open access data, 190–191
 current and future trends in, 198–199
 disclosure of research findings and, 231–234
 duty of confidence and privacy of, 245–246
 EGA and, 192
 group privacy protections in, 243–245
 health research regulation and, 7–8
 informed consent and, 103–104
 integrity and ethics protections, 188–189
 monitoring of data use and, 191–192
 in neuroscience, 308
 privacy rights and, 75–77
 producer rights and interests in, 189–190
 public engagement in, 116, 118–119
 public perceptions of, 217
 relationality in, 59–61
 rules-based vs. practice-based approaches in regulation of, 170–171
 subject rights and, 188–189
 trustworthiness of research governance and, 248–249
 value and social values in, 394–396
- Data Protection Act 2018 (DPA, UK)
 enactment of, 69
 HRR community lobbying and, 71–72
 neuroscience research and, 310–312
 research governance and, 167–169
- Data Protection Regulation 2016/679 (GDPR) (EU), 75–77
- data sharing
 governance frameworks for, 187–188
 informed consent and, 105–108
 in neuroscience research, 308
 participatory learning in regulatory governance and, 284–285
 privacy protection and, 73–74
 public engagement and, 116
 trustworthiness in, 87–89
- Datta, A. K., 376
- Davidson, S., 115–116
- Dawson, A., 91, 97
- decision-making
 accountability and risk aversion issues in, 211
 central objectives in, 208–209
 disclosure of research findings for purposes of, 231
 in global crisis emergencies, 317–318
 health research regulation and, 99–101
 inclusion and equality in, 127
 institutional influences on, 205–214
 institutional structure and composition and, 209–211
 path dependencies and historical influences in, 212–213
 privacy in, 75–77
 public interest and, 240–241
 public vs. private duties in, 211
 social value and, 54
- Declaration of Alma Ata (1978), 299–301
- Declaration of Chiang Mai, 300
- Declaration of Helsinki
 autonomy guidelines in, 27–29
 benefit sharing in, 151–152
 group access to research participation in, 172–173
 informed consent in, 105–107
 post-trial obligations in, 152–153
 social value in, 46–47, 52–53
 vulnerability guidelines in, 18, 90–91
- Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks*, 103–104
- De Cleen, B., 251–252
- deep learning, medical devices and, 281
- deferred consent, 107–108
- deficit model of public understanding, 112–113
- Degeling, C, 117
- deliberative practices
 diversity theory and, 252–253
 participatory health governance and, 124–126
 public expertise mobilisation and, 248–256
- Delphi policy study, 397–399
- democratic approach, patient and public involvement and, 121–123
- De Novo premarket review process (FDA), 278–281
- deontological theory, privacy and, 78–79
- descriptive argument for benefit sharing, 150–151
- diabetic retinopathy, software as medical device for diagnosis of, 278–281
- dialogue, public engagement and role of, 119–120

- digital consent technology, 110
- DiMaggio, P., 210
- direct benefit
- in RCTs, 133
 - social value as, 49–51, 53–54
- disaster research
- global health emergency guidelines and, 316–317
 - public engagement in, 319–320
 - risk assessment in, 199–200
 - social value of, 317–318
- disclosure of research findings
- criteria for disclosure, 231
 - ethical issues linked to, 229–238
 - guidelines and recommendations about, 230–231
 - informed consent and, 107
 - narrative function of results, 235–236
 - participant's interests and, 234–235
 - physical integrity and identity and, 385–386
- discourse ethics, privacy and, 79–80
- discrimination, in vulnerability research, 20–22
- distributed responsibility, governance and, 123–124
- diversity, public expertise mobilisation and, 253–255
- Dixon-Woods, Mary, 179–180
- Dove, Edward S., 30–31, 34–35, 99–101
- downstream research, national policy frameworks for
- genetics and, 337–340
- duress, informed consent and, 107–108
- duty of care, disclosure of research findings and, 233
- duty to participate principal, disclosure of research findings and, 234–235
- Dworkin, Gerald, 29–30
- Dworkin, Ronald, 272
- dynamic consent, 110, 248–249
- Ebola outbreak
- experimental interventions and vulnerability in, 92–93
 - randomized controlled clinical trials in, 132–134
 - unregistered interventions in, 319
- Eckstein, Lisa, 231
- EC Regulation 141/2000, 62–63
- Editas company, 143–146
- Edwards, Robert, 373–374
- effectiveness of medical devices, marginalised focus on, 162–165
- efficacy
- social value and estimation of, 53–54
 - in traditional medicine, research on, 299–301
- egalitarian diversity and inclusiveness, 252–253
- Egelie, Knut, 143–144
- Eisenberg, Rebecca, 141
- electronic signatures, informed consent and, 110
- Emanuel, E., 46–47, 180–181
- empowerment
- participatory health governance and, 124–125
 - public engagement and, 116
- enforceable norms, solidarity and, 58–59
- engagement, proportionality and, 44–45
- enhancement innovations, development of, 383–384
- epistemic injustice, relational autonomy and, 35–36
- epistemic integration, medical device failure and, 165–166
- Epstein, S., 127
- equality
- diversity theory and, 252–253
 - non-invasive prenatal testing and, 267–268
- Ethical and Policy Issues in International Research* (National Bioethics Advisory Commission), 151–152
- ethical issues in health research
- autonomy guidelines, 27–29
 - benefit sharing and, 151–153
 - in Big Data research, 123
 - bioethics advisory committees, 220–222
 - chimeric research oversight and guidelines and, 359–362
 - data protections and, 188–189
 - disclosure of research findings and, 229–238
 - enhancement innovations and, 383
 - ethical approvals process and, 307–309
 - ethical licensing, 145–146
 - evaluation of regulatory changes and, 202–203
 - exemption for types of research, 200–201
 - future directions in, 182–185
 - genome-editing and, 267–268
 - global health emergencies and, 315–323
 - health policy formation and, 217–218
 - human-technology embodiment and, 384–386
 - incidental findings and, 229–230, 309–310
 - interspecies research, 357–358
 - learned and academic societies' influence on, 220
 - learning healthcare systems and, 391–394
 - Learning Health Research Regulation System and, 394–396
 - net risk test and, 136–137
 - neuroscience and, 304, 310–312
 - participants' interests and needs and, 234–235
 - placebo controls in evidence-based medicine and, 299
 - politics and, 92–93
 - prenatal testing and, 267–268
 - process simplification and harmonisation and, 200–201
 - protection of culture and, 242n.23
 - randomized controlled clinical trial and, 132–134
 - regulatory design and, 182–184
 - regulatory process and, 178–180
 - relational autonomy and, 30–33
 - reproductive medicine and, 375–377
 - research integrity and, 188–189
 - review as regulatory process in, 178–180
 - review of, 177–186
 - risk identification and, 130–132
 - standardisation of review processes, 182–184
 - vulnerability guidelines, 17–18
 - in vulnerability research, 20–22
- ethical licensing, 145–146
- Ethics Advisory Board (US Dept. of Health, Education and Welfare), 366–368
- Ethics Guidelines for Trustworthy AI* (EC), 271
- Ethics Review Committee (WHO), 320–322
- The Ethics of Research Related to Healthcare in Developing Countries* (Nuffield Council on Bioethics), 151–152
- EU Directive 95/46/EC, 167–168, 171

- EU Directive 2001/20/EC, 200–201
- EU Directive 2004/24/EC, 300–301
- EU Regulation 2017/745, 382–383
- EU Regulation 2017/746, 382–383
- Europe, health research regulation in, 1
- European Commission
- benefit sharing guidelines, 154–156
 - Guidelines for Trustworthy AI, 175
 - risk-benefit analysis guidelines, 137
- European Convention on Human Rights (ECHR), 74–75, 245–246
- European Court of Human Rights, 75, 245–246
- European Directive on Traditional Herbal Medicine Products (THMPD), 297–298
- European General Data Protection Regulation, 105–106
- European Genome-phenome Archive (EGA), 192
- European Group on Ethics in Science and New Technologies to the European Commission, 151–152
- European Medicines Agency (EMA)
- advanced therapies regulation and, 324
 - Argentinian regulatory harmonisation with, 328–329
 - regulatory science and, 394
 - reproductive medicine add-on services regulation and, 377–379
- European Open Science Cloud (EOSC), 7–8
- European Union (EU)
- Data Protection Regulation 2016/679 (GDPR), 75–77
 - data protection regulation in, 67–70, 167–169, 171, 243–245
 - medical device approvals by, 160–161
 - medical device regulation in, 386–389
 - regulatory regime in, 14, 56
 - traditional and herbal medicine regulation in, 300–301
- European Union Clinical Trials Directive, 6–7, 130–132, 199–200, 340–341, 347–348
- evidence-based healthcare. *See also* non-evidence-based medicine
- Big Data research and, 257–259
 - economics of clinical guidelines and, 301–302
 - health policy formation and, 216–218
 - learned and academic societies' evaluation of, 220
 - norms of evidence and, 303–304
 - placebo controls and, 298–299
 - risk-benefit analysis and ethics review and, 137–138
 - traditional and alternative medicines and, 296–305
- excessive risk, risk-benefit analysis and, 136–137
- exclusion criteria
- proportionality and, 40
 - in vulnerability research, 20–22
- existence conditions, automated healthcare regulation and, 272
- expectations in health research
- Argentinian regulation of, 327–328
 - failure and, 159–162
 - neuroscience and, 308–309
 - reproductive immunology mythology and, 376–377
 - reproductive medicine and role of, 374
- experimental interventions
- global health emergencies and, 318–320
 - vulnerability and, 92–93
- experts and expertise
- evidence-based medicine and, 298–299
 - future of health research regulation and, 222–224
 - health policy advice and, 215–224
 - learned and academic societies, 218–220
 - mobilisation in health research regulation of, 248–256
 - representation and inclusiveness issues in, 251–253
- explicability, artificial intelligence and, 271
- exploitation
- group vulnerability to, 93–95
 - vulnerability in health research and, 91–92
- externalist perspective, relational autonomy and, 31
- external validity, in RCTs, 133
- facilitative leadership
- participatory governance and, 128–129
 - proportionality and, 42–43
- failure in health research
- expectations and, 159–162
 - history of, 158
 - legal interpretations and constructions of, 161–162
 - risk assessment and prevention, 158–166
 - systemic causes of harm and, 162–165
 - values failure, 395
- failure of care data, public interest in HRR and, 69–70
- fair benefits model, benefit sharing and, 153
- Fairmichael, F., 395
- fairness
- artificial intelligence and, 271
 - non-invasive prenatal testing and, 267–268
- fair participation, global health emergency research and, 318–320
- Federal Advisory Committee Act (US), 220–221
- Federal Policy for the Protection of Human Subjects (Common Rule, US), 46–47, 182–184, 199–201, 223
- Federal Regulations on Research With Human Participants (US), 130–132
- federal science advisor, 222–223
- feedback policies
- disclosure of research findings and, 231–234
 - ethical responsibilities in, 236–238
 - participants' interest and, 234–235
- Feeney, Oliver, 143–144
- fertility medicine. *See in vitro* fertilisation; reproductive medicine
- fictional man paradigm, public interest litigation and, 69
- final cause/objective, of institutional decision-making body, 208–209
- Financial Services Authority (FSA, UK), 257–259
- Fineman, M. A., 19
- first-order proportionality, defined, 37–38
- Fish, Stanley, 210
- 510(k) pathway, medical device trials, 279–281
- Flear, Mark, 158–166
- flexibility, in health research governance, 259–260
- Foley, T., 395
- follow-on research, non-exclusive research tool licensing and, 142–143
- Food, Drug and Cosmetic Act (US), medical device definition in, 278–281

- Food and Drug Administration (FDA, US)
 advanced therapies regulation and, 324
 Argentinian regulatory harmonisation with, 328–329
 clinical decision support software and, 277–278
 IDx-DR AI diagnostic system approval by, 278–281
 medical device approvals and, 160–161
 minimal risk principle in regulations and, 199–200
 politics and, 216–218
 premarket review proposal, 282–283
 risk-based medical device classification, 279
 risk-benefit analysis in, 134
 waivers of consent and, 200–201
- foresighting, anticipatory knowledge and, 285–286
- forms of engagement, health regulation research and, 14
- for-profit health research, benefit sharing and, 154–156
- Foucault, Michel, 163, 383
- foundational research tools, non-exclusive research tool
 licensing, 142–143
- Four Principles, 169–170
- 14-day rule
 embryo research and, 365–372
 evolution of, 366–368
 grounds for revisiting, 370–372
 in HFE ACT, 367
 special status principle and, 367–370
 theoretical basis for, 368–370
- Franklin, Benjamin, 220–221
- free riders argument, enforceability of solidarity and,
 58–59
- Frewer, L. J., 114
- Fricker, Miranda, 90nn.1–2
- Friedman, Marilyn, 31
- Friesen, Phoebe, 202, 299
- Fukushima disaster, emergency healthcare and, 319–320
- functional complementarity, 264
- Fung, A., 124–125, 127–129
- Gallagher, N., 118
- Ganguli-Mitra, Agomoni, 92–93, 275–276, 315–323
- Gash, A., 124–125, 128–129
- gastrulation, human embryo research and, 368–370
- Gelsinger, Jesse, 222
- gender equity
 autonomy and, 31
 benefit sharing and marginalisation of, 152–156
 medical device failure and marginalisation of, 162–165
 physical integrity and identity and, 385–386
 reproductive medicine and, 354–355
- Gene Editing Summits, 335–336
- gene-editing techniques, balancing of interests and,
 267–268
- General Data Protection Regulation (GDPR, EU), 67–70,
 167–169, 171, 243–245
 procedural complementarity in, 264
- General Guidelines for the Research of Non-Conventional
 Medicines* (WHO), 299–301
- General Medical Council (GMC), 377–381
- general public, classification of, 117
- gene therapy research, 222
- genetics research
 Argentinian genetically modified crops, 324–325
 co-dependent human-technology embodiment and,
 383–384
 cultural protections and, 242n.23
 group vulnerability and, 95–97
 harmonization of regulations on, 341–343
 human gene editing, 335–343
 interspecies research, 356–364
 risk identification in, 130–132
- genomic initiatives, 103–104
 co-dependent human-technology embodiment and,
 383–384
 disclosure of research findings and, 231–234
 ethical licensing for, 145–146
 human genome definitions in, 346–348
 normative systems regulation, 336–341
 participants' interest in, 234–235
 probabilistic vs. predictive results in, 232–233
 regulation of, 267–268
- Genomics England initiative, 6, 103–104
- Genotype/Phenotype database (dbGaP), 193
- Ghinea, Narcyz, 287–295
- Giddens, Anthony, 257
- Global Alliance for Genomics and Health, 103–104, 195
- Global Code of Conduct for Research in Resource-Poor
 Settings*, 152
- global health emergency research (GHER)
 data sharing in, 87–89
 emergency context in, 316–317
 future issues and challenges in, 322–323
 governance and oversight guidelines and practices,
 320–322
 justification for, 318–320
 social value and ethics in, 51–52
 trustworthy institutions in, 81–89
- global non-autonomy, situational vulnerability and, 33
- Glover, Anne (Dr.), 222–223
- Good Clinical Practice* (WHO), 152
- Good Clinical Practice Guidelines* (ICH), 105–106,
 173–175
- good will, trust and, 84
- Google Deep Minds' health data processing project,
 118–119
- Gotze, J., 119–120
- Governance Arrangements for Research Ethics
 Committees (GafREC), 179
- governance of research. *See also* participatory governance
 adaptive governance, Big Data research regulation,
 257–265
 Argentinian cell therapy research, 325–326
 benefit sharing and, 151–153
 data governance frameworks, 59–61, 187–196
 data subject rights, 188–189
 defined, 257
 ethical approvals process and, 307–309
 genomics research, normative framework in, 336–341
 global health emergency research, 320–322
 health research regulation and, 1–2, 14
 implementation of effective models, 260–263
 inefficiencies in, 202

- innovation oversight and, 292–295
 institutional dimensions of health research and, 205–214
 international health policy frameworks and, 340–341
 learned and academic societies as experts for, 218–220
 national policy frameworks for genetics and, 337–340
 in neuroscience, 304, 310–312
 patent regulation and, 141–142
 principles-based regulation and, 257–259
 privacy and, 77–80
 public engagement and, 119–120
 rule, principles and guidance-based initiatives, 167–176
 structures and processes, 263–265
 trustworthiness of, 248–249
- group-level solidarity, 58–59
 health research and, 59–61
- groups
 common interest and privacy of, 241–243
 legal privacy protection for, 243–246
 risk identification in research on, 130–132
 vulnerability in health research for, 93–95
- Guerrini, Christi, 145–146
- Guideline 20 (CIOMS), 320–322
- Guidelines for Human Experimentation* (Germany), 17–18
- Guidelines for Methodologies on Research and
 Evaluation of Traditional Medicine (WHO),
 297–298
- Guidelines for Trustworthy AI (European Commission),
 175
- Gusterson, Hugh, 285–286
- H3Africa benefit sharing initiative, 153
- Haas, Nayeli Urquiza, 296–305
- Habets, M., 53–54
- Hacking, Ian, 285–286
- Hancock, Matt, 271
- harm
 artificial intelligence and prevention of, 271
 automated healthcare and, 266–274
 in Big Data research, 123
 expectations and failure involving, 160–162
 future harm, prevention of, 158–166
 in global crisis emergencies, 317–318
 group vulnerability and, 97
 proportionality of, 39–40
 risk identification and, 130–132
 social value and, 54
 systemic causes of, 162–165
- Hamon, Shawn H. E., 382–390
- harmonization of regulation, genetics research and,
 341–343
- Harper, Steven, 216–218
- Hastings Center Report, social value in, 51–52
- Havasupai tribe, 138
 health research on, 130–132
 protection for, 242n.23
- Hawley, K. J., 88n.45
- Health and Care Act 2012 (UK), 301–302
- healthcare
 access to, 59–62, 154–156
 automated healthcare, 266–274
 disclosure of research findings and, 231–234
 failure of care data, 69–70
 regulatory regimes vs., 6
 research and, 6
 research-therapy divide in technology governance and,
 277–286
 resistance to participatory governance in, 125
 health research, value-driving paradigm for, 394–396
- Health Research Authority (HRA) (UK), 205
 Confidentiality Advisory Group (CAG), 212–213
 institutional overview of, 208–209
 Proportionate Review Service, 182–184
 public interest guidelines, 67–70
- health research regulation
 Argentinian advanced therapies research, 324–331
 automated healthcare, 266–274
 benefit sharing and, 148–157
 best practices and, 173–175
 clinical innovation and barrier of, 287–290
 countervailing trends in, 201–202
 current and future trends in, 197–203
 design innovations in, 182–184
 disclosure of findings, protocols for, 229–238
 evaluation of changes to, 202–203
 expert and advisory advice in, 215–224, 248–256
 failure in, 158–166
 future issues for, 222–224
 human embryo research, 365–372
 human gene editing, 335–343
 human germline research, 350–352
 institutional influence in, 205–214
 interspecies research and, 356–364
 key concepts in, 13–15
 learned and academic societies' influence on, 218–220
 of medical devices, 277–286, 382–390
 in neuroscience research, 304
 non-evidence based reproductive medicine and,
 373–381
 patent regulation, 139–147
 policy advice sources in, 215–224
 privacy and public interest in, 239–247
 problems and issues with, 1–3
 process simplification and harmonisation and, 200–201
 public interest appeals in, 66–67
 recent changes in, 3–5
 responsive regulation development, 333–334
 review as regulatory process and, 178–180
 risk-benefit analysis in, 130–138
 rule, principles and guidance-based initiatives, 167–176
 shared practices in, 59–61
 software as medical device and, 277–286
 solidarity in, 56–64
 supplementary guidance and, 173–175
 traditional and non-conventional medicines, 296–305
 visibility of, 264–265
- health research systems
 informed consent and evolution of, 103–104
 participatory governance in, 123–126
- health systems research, social value in, 51–52
- He Jiankui, 345–346, 351, 354–355

- Held, V. P., 240
- Heller, Michael, 141
- hematopoietic progenitor cells (HPC), Argentinian
regulation of research on, 326–328
- Hendl, Tereza, 287–295
- Heneghan, Carl J., 160–161
- High Level Expert Group (HLEG), 7–8
- Hilgartner, Stephen, 139
- Hinterberger, Amy, 356–364
- Hirsch Index, 47–49
- historical influences, institutional decision-making and,
212–213
- Ho, Calvin W. L., 277–286
- Hodgson, G. M., 207–208
- Hoffmann (Lord), 245–246
- homeopathic practices, guidelines for, 301–302
- homogeneity
of institutions, 213
vulnerability and, 33–34
- Horizon Programme, 152
- human assemblage ideology, human-technology
embodiment and, 384–386
- human-centric governance, automated healthcare
regulation and, 272
- human challenge trials, debate over, 318–320
- human embryo research
admixed embryos, 358–359
evolution of regulatory framework for, 366–368
14-day rule and, 365–366
interspecies research and, 356–364
regulation of research on, 365–372
revisiting 14-day rule in, 370–372
special status principle in, 367–368
terminology and definitions of, 347–348
threshold of humanity principle and, 370–372
- Human Fertilisation and Embryology Act and Authority,
HFEA (1990, UK)
Code of Practice, 378–379
data protection regulation in, 171
human embryo research and, 358–359, 365–368
human germline research and, 346–350
reproductive immunology warning and, 376–377
reproductive medicine add-on services and, 378–379
revisions to, 368–370
in vitro fertilisation licensing and, 374
- human gene editing
harmonization of regulations on, 341–343
international health policy frameworks and, 340–341
moral concerns over, 336–341
national policy frameworks for, 337–340
normative regulatory systems for, 335–343
slippery slope ideology and, 349–350
- Human Genome Organization (HUGO), 149–151
- Human Genome Project, 103–104
open access and, 190–191
- human germline research
context in, 348–350
ethical debates over, 344–355
future research challenges in, 354–355
global regulation and scientific justice, 352–353
- harmonization of regulations on, 341–343
- international health policy frameworks and, 340–341
- national policy frameworks for, 337–340
- normative regulatory framework for, 336–341
- overview, 345–346
- regulation, responsibility and cooperative research in,
350–352
- terminology and definitions, 346–348
- humanitarian crises
health care regulation and, 199
research ethics in, 315–323
social value of research in, 317–318
- humanity, threshold of
enhancement innovations and, 383
human embryo research and, 370–372
- Human Medicines Regulations 2012 (UK), 377–379
- Human Reproductive Cloning Act (2001, US), 347–348
- human rights
automated healthcare regulation and, 270
disclosure of research findings and, 233–234
duty of confidence and, 246
genetics research regulation and, 340–341
human embryo research and, 366–368
identity as human right, 390n.49
privacy as, 74–75
- Human Rights Act 1998 (UK), 245–246
- Human Tissue Act 2004, 212–213
- Human Tissue Authority, 205
- human values, health research regulation and, 7
- Hunt, Matthew, 315–323
- Hurricane Katrina, distrust of government response in,
319–320
- Hurst, S. A., 21–22, 25
- Hutter, B., 161–162
- hypothesis-driven trials, social value of, 54
- Hyun, Insoo, 361
- idem* principle of identity, 384–386
- identity
disclosure of research findings and, 229–238
human-technology embodiment and, 384–386
narrative as, health research participation and, 235–236
right to, 390n.49
- IDx-DR AI diagnostic system, risk assessment and market
approval, 278–284
- IMDRF (International Medical Device Regulators
Forum), software as medical device regulations and,
282–283
- Immergut, E., 208
- incidental research findings, 229–230
in neuroscience research, 309–310, 313
- inclusiveness
in health research governance, 259–260
non-invasive prenatal testing and, 267–268
- inclusive public engagement
data intensive health research and, 118–119
public expertise and, 251–253
- incommensurability, proportionality and, 41–42
- independent, interdisciplinary data access, 193–194
- independent review boards, privacy and, 75–77

- Indian Ocean tsunami, emergency healthcare and, 317–320
- indirect benefit, in RCTs, 133
- individuals and individualism
- autonomy guidelines in research ethics and, 29–30
 - data governance and, 59–61
 - group vulnerability and, 95–96
 - health research regulation and, 7, 14
 - individual vulnerability in research, 92–93
 - institutional decision-making and role of, 211
- informational privacy, 75
- data protection and, 75–77
 - risks to, 130
- information technology, collaborative licensing, 144–145
- informed consent
- alternate models of, 200–201
 - basis for, 104–105
 - in Big Data research, 123
 - consent to contact policies and, 201–202
 - cultural factors in, 242n.23
 - data protection and, 67n.15
 - digital consent mechanisms and, 110
 - evolution of health research and, 103–104
 - fetishisation of, 181–182
 - group vulnerability and, 95–96
 - legal requirements for, 105–108
 - limitations of, 108–109
 - overview of, 103
 - privacy and, 75–77
 - proportionality and, 40
 - relational autonomy and, 30–31, 34–36
 - right of refusal and, 108
 - solidarity in health research and, 59–61
 - trust and, 248–249
 - vulnerability and, 17–18, 20–22
 - waivers of, 199–200
 - written forms of, 108–109
- infrastructural vulnerability, health research regulation and, 396, 23–24
- inherent vulnerability, 33
- innovative health research
- autologous mesenchymal stem cell intervention, 290–292
 - clinical innovation in medical marketplace, 287–295
 - collaborative licensing and, 144–145
 - conflicts of interest in, 292–295
 - disturbance of regulation from, 382–383
 - emerging science and technology oversight and, 397–399
 - enhancement innovations, 383–384
 - ethical licensing and, 145–146
 - government intervention and, 141–142
 - market forces and, 140–141, 292–295
 - medical device regulation and, 386–389
 - national policy frameworks for genetics and, 337–340
 - oversight and, 287–290, 292–295
 - overuse of non-evidenced based therapies, 292–295
 - patent regulation and, 139–147
 - patent rights and, 141
 - self-regulatory patent rights models and, 142–146
- Institute of Medicine (IOM, US), 124, 391–394
- Institutional Animal Care and Use Committee (IACUC), 360
- institutional capture, public engagement and, 118–119
- institutional review boards (IRBs)
- design and performance criticism of, 180–181
 - purpose of, 177–178
 - risk-benefit analysis and, 137–138
 - single board (sIRB), 200–201
- institutions
- accountability and risk aversion issues in, 211
 - context of, 207–208
 - decision-making body objectives in, 208–209
 - decision-making body structure and composition, 209–211
 - defined, 207–208
 - design of, participatory governance and, 127–129
 - health research regulation and, 14–15, 205–214
 - influences on decision-making in, 208–213
 - inter-institutional influences in, 213
 - path dependencies and historical influences in, 212–213
 - public vs. private duties in, 211
 - solidarity of, health research and, 59–61
 - trust in, 86–87
- instrumentality, public engagement and, 113–116
- integrity, human-technology embodiment and, 384–386
- intellectual property rights
- collaborative licensing and, 144–145
 - patent regulation and, 140–141
- intended research findings, 229–230
- interconnectedness
- in health research regulation, 2
 - learning healthcare systems and, 391–394
- inter-institutional design
- health research regulation and, 213
 - learning healthcare systems and, 391–394
- Interministerial Commission for Research and Medicaments of Advanced Therapies (Argentina), 328–329
- internal validity, in RCTs, 133
- International Bioethics Committee (UNESCO), 340–341
- International Cancer Genome Consortium/25K Initiative, 193
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 105–106
- International Covenant on Civil and Political Rights (UN), 105–106
- International Ethical Guidelines for Health-related Research, 46–47
- International Ethical Guidelines for Health-Related Research Involving Humans* (CIOMS), 35–36, 46–47, 169, 199–200
- international health policies
- genetics research regulation and, 340–341
 - human germline research, 352–353
- International Organization for Standards (ISO), 167–168, 282–283
- interpersonal solidarity, 58–59
- interpretive community, 210
- disclosure of research findings and, 236–238

- interspecies biomedical research
 chimeric organisms, 357–358
 regulation of, 356–364
 shifting regulatory boundaries in, 362–363
 vulnerability issues, 363–364
- interventions
 autologous mesenchymal stem cell case study, 290–292
 clinical innovation oversight and, 287–290
 component risk-benefit analysis, 135–136
 risk identification in, 130–132
 social value of, 49–51, 53–54
in vitro fertilisation add-on procedures, 375–377
- intrauterine culture, absence of effectiveness research on, 379
- investigational therapeutics, global health emergencies and use of, 319
- In Vitro Diagnostic Medical Devices Regulation (IVDR), 382–383, 386–389
- in vitro* fertilisation (IVF)
 add-on procedures in, 375–377
 costs of, 375
 culturing technological advances in, 368–370, 373–374
 failure rate in, 375–377
 14-day rule and, 365–366
 non-evidence-based medicine in, 373–381
 patient choice dynamics in, 380
 special status principle in, 367–368
 threshold of humanity principle in, 370–372
 time pressures in, 374–377
 Warnock Report findings and, 366–368
- ipse* principle of identity, 384–386
- Isasi, Rosario, 335–343
- isomorphism
 institutional decision-making and, 210
 inter-institutional influences and, 213
- issue characteristics, rare disease research, 61–62
- Jackson, Emily, 373–381
- Jacobs, Marie Andree, 304
- Jasanoff, Sheila, 306–307
- Johnson, Summer, 218
- justice
 autonomy guidelines and, 27–29
 as benefit sharing argument, 150–151, 154–156
 human germline research, 352–353
 informed consent and, 104–105
 medical device failure and, 162–165
- Kant, Immanuel, 78–79
- Kaye, Jane, 103–111
- Kerasidou, Angeliki, 14–15, 81–89
- Kerridge, Ian, 287–295
- Kieslich, Katharina, 14, 56–64
- Kipnis, K., 396, 23–24
- Klitzman, R., 203
- Knight, D., 159–160
- knowledge production
 failure as tool for, 162–165
 medical device failure and organisation of, 162–165
 participatory government and forms of, 126–127
 participatory health governance and, 285–286
 risk-benefit analysis and, 132–134
- Koops, Bert-Jaap, 273
- Kurunmäki and Miller, 159
- labelling approach, vulnerability research and, 20–22
- ladder of public participation, 114, 116
- Lane, Neal, 223–224
- Lange, M. Meeke, 23–24
- Langwick, Stacey, 304
- Laurie, Graeme, 1–10, 165, 264–265, 277–278, 285–286, 391–400
- laws and legislation
 Argentinian health research regulation and, 330–331
 data protection law, 243–245
 fetishisation of consent and, 181–182
 genomics research and, 336–341
 group privacy protections and, 243–246
 human embryo special status in, 367–368
 informed consent and, 108–109
 institutional decision-making and, 212–213
 medical device regulation and, 388–389
 physical integrity and identity in, 385–386
 politics and barriers to, 223
 privacy and, 241–243
 public interest and, 67–70
 shifting regulatory boundaries in animal research and, 362–363
 traditional and non-conventional medicines and, 303–304
- leadership support, participatory governance and, 127–129
- learning healthcare systems
 continuous learning and research-therapy divide in, 277–286
 current and future trends in, 199
 disclosure of research findings and, 231–234
 minimal risk principle and, 199–200
 patient engagement in, 124
 regulatory science and, 391–394
 risk identification in, 130–132
- Learning Health Research Regulation System (LHRRS)
 basic goals and features of, 399–400
 ecosystem for, 397–399
 learning healthcare systems and regulatory science and, 391–394
 overview of, 1–10
 proposals for, 5, 391–400
 value and social values in, 394–396
- legitimacy
 medical device failure and, 163–164
 of public engagement, 250–251
 public interests and, 240–241
- Lemley, Mark, 140–141
- Leopoldina Society, 218, 220
- licensing
 collaborative licensing, 144–145
 ethical licensing, 145–146
 mixed licensing models, 143–144
 non-exclusive research tool licensing, 142–143
 reproductive medicine add-on services, 377–379

- temporary licensing, 165
- in vitro* fertilisation and, 374
- lifecycle assessment, software as medical device regulations and, 282–283
- liminality
 - advisory bodies and, 221
 - AI/ML device regulation and, 278
 - artificial intelligence and, 277–278
 - health policy advice and, 215–216
 - health research regulation and, 222–224
- Liminal Spaces Project, 3
 - emerging science and technology oversight and, 397–399
- limited disclosure of information, informed consent and, 107
- Lipworth, Wendy, 287–295
- Lloyd-Bostock, S., 161–162
- local governance reviews
 - global health emergencies and, 319–320
 - inefficiencies with, 202
- Long Term Plan* (NHS), 271
- low-and-middle income countries (LIMC)
 - benefit sharing in, 152–156
 - biotechnology regulation in, 324–325
 - global health emergencies in, 317–318
 - regulatory thresholds in, 353
 - trust in health research in, 81–82, 85–86
 - vulnerability of groups in, 93–95
- Lowi, Theodore, 61–62
- Luna, F., 23–24
- Lysagt, Tamra, 287–295
- MacCormick, N., 208–209
- machine learning
 - IDx-DR AI diagnostic system, 281–284
 - as medical device, 277–286
- Mackenzie, Catriona, 32
- maker movement, evolution of, 382–383
- Managing Ethico-social, Technical and Administrative Issues in Data ACess (METADAC, UK), 126
- March, J., 209–211
- Margulis, S. T., 242
- market forces
 - autologous mesenchymal stem cell case, 290–292
 - clinical innovation and, 287–295
 - medical device regulation and, 382–383, 386–389
 - overuse of non-evidenced based therapies and, 292–295
 - patent regulation and, 140–141
 - in reproductive medicine, 375–377
- Markingham, Dan, 21
- May, William, 178
- Mayo Clinic Biobank deliberation, 125–126
- McLeod, Carolyn, 32, 34–35
- McMillan, Catriona, 333–334, 365–372
- Medical Assistance in Dying and When Antibiotics Fail* (CCA), 219–220
- medical devices. *See also* software as medical device (SaMD)
 - artificial intelligence/machine learning as, 277–286
 - clinical trials for, 279–281
 - current and future regulation concepts and perspectives, 382–390
 - expectations for, 160–162
 - failure of, 158–166
 - future challenges in regulation of, 389–390
 - knowledge base for, 162–165
 - market forces in regulation of, 386–389
 - participatory learning in regulatory governance of, 284–285
 - post-market surveillance of, 388–389
 - re-embedded risk and sociality and, 281–284
 - risk-based FDA classification of, 279
 - temporary licensing for, 165
- Medical Devices Regulation (MDR, EU), 161, 386–389
- Medicines and Healthcare Products Regulatory Agency (UK), 205, 377–379
- Médecins sans Frontières, 132–133
- Medina, José, 35–36
- Megan's Law, 285–286
- mental health research, risk identification in, 130–132
- Meslin, Eric M., 215–224
- Mesmer, Anton, 220–221
- METADAC (Managing Ethical, Sociotechnical and Administrative issues in Data Access), 193–196
- metal-on-metal hips, expectations and failure involving, 160–162
- MEURI (monitored emergency use of unregistered and experimental interventions) scheme, 319
- Mexican General Health Law, 97
- Mill, John Stuart, 78
- Miller, Franklin, 235, 399–400
- Millum, Joseph, 51–52
- mimetic isomorphism, 213
- minimal risk principle, health research regulation and, 199–200
- mitochondrial replacement therapy (MRT)
 - emergence of, 344–345
 - terminology and definitions of, 347
- mixed licensing models, patent regulation and, 143–144
- Mode 2 research, social values and, 47–49
- Moffett, A., 376
- monitoring, in health research governance, 259–260
- moral agency
 - automated healthcare regulation and, 273–274
 - global health emergencies and, 321–322
 - human-technology embodiment and, 384–386
 - trust and, 85
 - trustworthy institutions and, 86–87
- moral hazard, mixed licensing model and, 143–144
- multi-agency research networks
 - learning healthcare systems and, 391–394
 - participatory health systems governance and, 126
- multi-disciplinary efforts
 - institutional decision-making and, 210–211
 - learning healthcare systems and, 391–394
- multilevel engagement strategies, participatory governance and, 128
- Munsie, Megan, 287–295
- Murtagh, M. J., 126
- my data phenomenon, health research regulation and, 8–9

- Nabatchi, T., 254–255
- Nagoya Protocol on Access and Benefit-Sharing, 149
- narrative tools, research findings as, 235–236
- National Academies of Sciences, Engineering and Medicine (NASEM, US), 219–220
- National Academy of Science (NAS), chimera research guidelines, 359–362
- National Administration of Drugs, Food and Medical Technology (ANMAT), 325–329
- National Agency of Promotion of Science and Technology (ANPCYT, Argentina), 325–326
- National Bioethics Advisory Commission (NBAC, US), 221–222
- National Bioethics Advisory Commission (US), 151–152
- National Commission for Agricultural Biotechnology (CONABIA) (Argentina), 324–325
- National Consultative Committee on Ethics (France), 221
- National Electronic Health Record System (NEHRS) (Australia), 118–119
- National Health Service (NHS)
- fertility treatment funding in, 375
 - non-conventional treatment regulation and, 301–302
 - research ethics and, 179
- National Institute for Health and Care Excellence (NICE, UK), 173–175, 301–302
- in vitro* fertilisation guidelines in, 375
- National Institute for Transplantation (INCUCAI, Argentina), 325–328
- National Institutes of Health (NIH, US), 142–143
- chimeric research moratorium, 359–362
- national policy frameworks, genetics research and, 337–340
- National Statement on Ethical Conduct in Human Research* (Australia NHMRC), 105–106
- natural ecosystem, health regulation and role of, 268–269
- natural killer cells, reproduction medicine and mythology
- about, 375–377
- negative function, innovation oversight and, 292–295
- net risk test, risk-benefit analysis and, 136–137
- networks of actors, adaptive governance and, 263–265
- neuroimaging techniques, ethical issues and, 307–309
- neuroscience research
- ethics, governance and practice in, 304
 - incidental findings in, 309–310, 313
- ‘A New Pathway for the Regulation and Governance of Health Research’ (AMS report), 3–4
- New Zealand, evidence-informed health policy in, 216–218
- NHS Act 2006, 167–168
- Section 251, 68
- NHS Trusts, 205
- NHSX (UK), 271
- Nicholls, Stuart G., 197–203
- Nickel, P. J., 23–24
- Nicol, Dianne, 139–147
- Nielsen, Jane, 139–147
- non-assertion covenants, patent regulation, 145–146
- non-conventional medicine
- history and evolution of, 296–298
 - research regulation of, 296–305
 - uncertainty of knowledges and practices and, 303–304
- non-evidence based medicine, *in vitro* fertilisation and, 373–381
- non-exclusive research tool licensing, patent rights and, 142–143
- non-identifiable data, duty of confidence and, 246
- non-invasive prenatal testing (NIPT), regulation of, 267–268
- non-maleficence
- informed consent and, 104–105
 - proportionality and, 40
- normative rationales
- autonomy and, 32
 - disclosure of research findings and, 233–234
 - genomics research, 336–341
 - human embryo research and challenges of, 366–370
 - human gene editing regulations, 335–343
 - incidental research findings and, 309–310
 - learning healthcare systems and, 391–394
 - in neuroscience research, 308–312
 - normative isomorphism, 213
 - normic diversity, 252–253
 - principles-based regulation and, 259
 - privacy protection and, 73–74
 - public engagement and, 113–116
 - rules- and principles-based regulation and, 169, 172–173
- North, D., 207–208
- Notice of Proposed Rule Making, 202–203
- Nowotny, H., 48–49
- Nuffield Council on Bioethics, 151–153, 221, 267–268, 320–322
- Nuremberg Code, 17–18, 105–108, 169
- Nuu-chahnulth people, genetics research and, 242n.23
- Obama, Barack, 216–218
- O’Doherty, Kieran C., 121–129
- OECD Guidelines on the Protection of Privacy and Transborder Flows of Personal Data*, 75–77
- off-label use of medicines, reproductive medicine add-ons, 377–379
- off-target humanised tissue, interspecies research and
- problem of, 360–361, 363–364
- Olsen, J., 209–211
- O’Mathuna, D., 321–322
- 100,000 Genomes project, 231–235
- O’Neill, Onora, 9, 248–249
- Ontario Cancer Research Ethics Board (OCREB), 200–201
- open data and open science
- data-driven research, 190–191
 - disclosure of research findings and, 231–234
 - health research regulation and, 8–9
 - patent regulation and, 141–142
 - trust and, 87–89
- Opinion on Ethical Aspects of Clinical Research in Developing Countries* (European Group on Ethics), 151–152
- optimism bias, overuse of non-evidenced based therapies and, 292–295

- organ donation/retention, regulations concerning, 212–213
- Organisation for Economic Co-operation and Development (OECD), data governance and, 190–191
- orphan drugs research
- societal reframing of, 63
 - solidarity in, 61–63
- Oshana, Marina, 31
- Ostrom, Elinor, 262–264
- Osuji, P., 108–109
- outputs of health research, 100
- over-inclusive labelling, vulnerability in research and, 21–22
- Oviedo Convention, 105–106, 340–341
- pain relief protocols, vulnerability and, 19
- Pang, T., 124
- participants in health research
- benefit sharing with, 154–156
 - disclosure of research findings and, 229–238
 - feedback to, 230
 - interests of, disclosure guidelines and, 234–235
 - in neuroscience research, 308
- participatory governance. *See also* governance of research
- clinical innovation oversight and, 289–290
 - enabling conditions for, 126–127
 - health research regulation and, 99–101, 121–129
 - health research systems, 123–126
 - institutional designs for, 127–129
 - international initiatives in, 124–125
- participatory learning systems, regulatory governance and, 284–286
- patent aggregation, 145
- patent pledges, 145–146
- patent pools, 144–145
- patent rights and regulation
- benefit sharing principle and, 150–151
 - ethical licensing, 145–146
 - government intervention and, 141–142
 - health research innovation and, 139–147
 - mixed licensing models, 143–144
 - non-exclusive research tool licensing, 142–143
 - as private regulation, 140–141
 - self-regulatory models for, 142–146
- paternalism, vulnerability in research and, 22
- path dependency, institutional decision-making and, 212–213
- pathogenic vulnerability, 91
- patient and public involvement (PPI). *See also* public engagement
- benefit treatment and, 54
 - consumerist and democratic approaches to, 121–123
 - disclosure of research findings and, 231–234
 - health research regulation and, 46, 48–49, 250–251
 - identity interests in, 397–399
 - increased demand for, 70–71
 - participatory governance in health research and, 121–129
- patient-centered care, learning healthcare systems and, 391–394
- Patient-Centered Outcomes Research Institute (PCORI, US), 126–127
- patient choice dynamics, reproductive medicine regulation and, 380
- patient health data
- consent to contact policies and, 201–202
 - disclosure of research findings and role of, 233
 - research regulations for use of, 167–168
- Patient Network for Advanced Therapies (APTA Network, Argentina), 329
- patterns of action, institutional decision-making and, 210–211
- PAWORNET system (Riles), 284–285
- perceptions of risk, risk-benefit analysis and, 134–135
- performance of medical devices, research focus on, 162–165
- permission to contact policies, 201–203
- permissive function, innovation oversight and, 292–295
- permitted embryo concept, 348–349n.26
- personal data protection, privacy and, 75–77
- Personal Genome Project, 103–104
- pharmaceutical industry, solidarity-based research and, 62–63
- placebo controls, evidence-based medicine and, 298–299
- placental sampling, autonomy and consent to, 30–31
- planned adaptations, research governance and, 264
- policy formation in health research
- Delphi policy study, 397–399
 - disclosure of research findings and, 229–238
 - evidence and evidence gathering and, 216–218
 - expert and advisory advice in, 215–224
 - future issues in, 222–224
 - genetics research regulation and, 336–341
 - international policy frameworks and, 340–341
 - learned and academic societies as experts for, 218–220
 - national genetics research frameworks for, 337–340
 - panaceas ideology in, 262–263
- politics in health research
- anti-science politics and, 216–218
 - group membership and, 95–96
 - group vulnerability and, 93–95
 - health research regulation and, 14–15
 - human germline research and, 352–353
 - individual vulnerability, 92–93
 - interspecies biomedical research regulations and, 362–363
 - non-traditional medicine and, 299
 - patent regulation and, 140–141
 - policy advice experts and advisory committees and, 215–224
 - protection and, 97
 - public expertise and, 251–252
 - trustworthiness and, 248–249
 - vulnerabilities and power in, 90–98
- polycentricity, Big Data research and, 257–259
- population groups
- data on, 118–119
 - in health research regulation, 59–61
- positive function, innovation oversight and, 292–295
- Postan, Emily, 229–238

- posthumanism
 enhancement innovations and, 383
 identity and integrity issues and, 384–386
- post-market surveillance, medical device regulation and, 388–389
- post-trial obligations, benefit sharing and, 152–153
- Potter, N. Nyquist, 84–85
- poverty, vulnerability and, 92–93
- Powell, W., 210
- power
 benefit sharing and role of, 154–156
 definitions and analysis of, 90–91
 group vulnerability and, 95–96
 participatory governance and devolution of, 127–129
 patent regulation and, 140–141
 resource imbalance with, 126–127
 trust and parity in, 85–86
 vulnerabilities in health research politics and, 90–98
 vulnerability and, 14–15
- Prainsack, Barbara, 14, 56–64
- precarity
 in global crisis emergencies, 317–318
 vulnerability and, 23–24
- Precision Medicine Initiative (PMI, US), 103–104, 122–123
- predictive influences, institutional decision-making in
 health regulation and, 208
- pregnancy
 non-invasive prenatal testing and, 267–268
in vitro fertilisation risks in, 375
 vulnerability of, 20–22, 33–34
- preparedness principles, in global health emergency
 research, 322–323
- preponderance theory, public interest and, 240
- prescriptive influences, institutional decision-making in
 health regulation and, 208
- Prictor, Megan, 103–111
- primary research, findings from, 229–230
- primitive streak development, human embryo research
 and, 367–370
- principles-based regulation
 AFIRRM model and, 260–263
 Big Data research, 257–259
 development of, 169–172
 health research regulation and, 167–176
 limitations, 172–173
- privacy
 atomistic conception of, 241–243
 in Big Data research, 123
 data access governance and, 188–189
 data protection law and, 243–245
 defined, 241–243
 duty of confidence and, 245–246
 group privacy, 241–243
 health research regulation and, 8–9, 14
 as human right, 74–75
 informed consent and, 75–77
 legal protection of group privacy, 243–246
 in modern context, 73
 normativity of, 73–74
 in personal data protection, 75–77
 public interest and, 239–247
 research governance and, 77–80
 risk to violation of, 130
- private sector healthcare
 genomics research and, 336–341
 learning healthcare systems and, 391–394
 medical device regulation and, 386–389
 misinformation about reproductive medicine and, 379
 patents as, 140–141
 reproductive medicine, 374, 377
- procedural ambiguity, neuroscience research and, 310–312
- procedural complementarity, 264
- professionalised lay experts, participatory governance and,
 127
- Professional Standards Authority (PSA, UK), 301–302
- progressive value, benefit analysis and, 53–54
- proportionality
 analytical complexities, 41–42
 defined, 37–38
 emerging science and technology oversight and,
 397–399
 in global health emergency research, 322–323
 of harms, 39–40
 health research regulation and, 13–15
 procedural approaches to, 42–45
 of review, 39–40
 social value and, 40–41
- protected experimental use, patent regulation and, 141–142
- protection, politics in health research and, 97, 141–142
- protocol risks, vulnerability of participants and, 21
- Public Accountability for Health-Related Research,
 CIOMS guidelines and, 47–49
- public engagement. *See also* patient and public
 involvement; patient and public involvement (PPI)
 anti-science politics and, 216–218
 consultation and, 115–116
 critique in, 112–113
 empowerment and, 116
 evaluation of, 119–120
 forms of, 113–116
 global health emergencies and, 319–320
 health research regulation and, 7, 99–101
 human germline research and, 354–355
 inclusive approach to, 118–119
 layers of, 114–115
 narrative of findings as tool for, 235–236
 overview, 112
 participatory learning in regulatory governance and,
 284–285
 public expertise mobilisation and, 248–256
 representation and inclusiveness issues in, 251–253
 trust and legitimacy challenges in, 250–251
 trustworthiness of research governance and, 248–249
 types of publics in, 117
- public expertise, mobilization of
 deliberation and, 253–255
 health regulation research and, 14
- public funding, patent regulation and, 141–142
- Public Health England, Value of Vaccines campaign, 115
- public interest

- automated healthcare and balancing of, 267–268
- CIOMS Public Engagement guidelines and, 47–49
- common interests and, 240–241
- contested concepts of, 65–66
- data acceptability and, 70–71
- data protection law and, 243–245
- decision-making in, 211
- deliberative public engagement and, 252–253
- health research regulation and, 13–15
- holistic concepts of, 71–72
- as legal device, 67–70
- privacy and, 78, 239–247
- trust and legitimacy challenges in, 250–251
- public-private models
 - genomics research regulation, 336–341
 - learning healthcare systems and, 391–394
- public reason, public interest and, 240–241
- pure public, classification of, 117
- Quality-Adjusted Life Years, proportionality and social value, 40–41
- Quality-Adjusted Time Without Symptoms and Toxicity (Q-TWIST) test, 138
- Quality Management System (QMS), AI/ML medical device regulation and, 283–284
- quandary ethics, medical device failure and, 163
- Raab, C. D., 241–243
- Rahmizadeh, V., 203
- Rai, R., 376–377
- randomised clinical trials (RCTs)
 - design in reproductive medicine for, 374–377
 - evidence-based medicine and, 298–299
 - global health emergency research and challenges of, 318–320
 - reproductive medicine and lack of, 373–374
 - risk-benefit analysis and, 132–134
- range of sensitivities, privacy and, 79
- rare disease research, solidarity in, 61–63
- Rawls, John, 49, 78–79, 240n.7
- Raz, Joseph, 31
- REACH platform, 284–285
- real-time responsiveness, global health emergencies and, 320–322
- reasonable availability model, benefit sharing and, 152–153
- reasonableness and reason-giving, diversity theory and, 252–253
- reasonable risk, risk-benefit analysis and, 136–137
- redundancy, Big Data research and, 257–259
- Reed, Chris, 277–278
- reflexivity, in health research governance, 259–260
- refusal, informed consent and right of, 108
- regenerative medicine
 - advanced therapies in, 324
 - Argentinian governance of research in, 325–326
 - regulation and oversight of, 359–362
 - vulnerability issues in, 363–364
- registrant risk assessment scale (RRAS), 285–286
- regulatory committees, institutional context for, 205
- regulatory/governance approach (RGA)
 - AI/ML medical devices and, 281–284
 - to health research, 167–168
 - participatory learning systems and, 284–286
- regulatory lapse, emerging technologies and, 167–168
- regulatory regimes
 - clinical care vs., 6
 - clinical innovation oversight and, 289
 - inefficiencies in committees, 201–202
 - innovation oversight and, 292–295
 - medical devices and changes in, 279–281
 - recent challenges for, 4–5
- regulatory responsibility
 - automated healthcare regulation and, 271–274
 - human germline research, 350–352
- regulatory science, learning healthcare systems and, 391–394
- relational autonomy
 - informed consent and, 34–36
 - participatory governance and, 127–129
 - principles of, 30–33
 - vulnerability and, 33–34
- reliability, trustworthiness and, 88n.45
- Reliable Replacement Warhead (RRW) program, 285–286
- reliance, trust in global health research and, 85–86
- representation and representativeness
 - group vulnerability and, 95–96
 - participatory governance and, 126–127
 - in public engagement, 251–253
- representative diversity, 252–253
- reproductive autonomy, non-invasive prenatal testing and, 267–268
- reproductive immunology
 - lack of research and regulation of, 375–377
 - off-label use of, 377–379
- reproductive medicine. *See also* cloning
 - add-on services regulation in, 377–379
 - alternative treatments in, 375–377
 - context in research on, 348–350
 - disclosure guidance in, 231, 233–234
 - evolution of regulatory framework for, 366–368
 - 14-day rule and, 365–372
 - global regulations and policies and, 352, 354–355
 - human gene editing and, 267–268, 336–341
 - innovation oversight in, 292–295
 - non-evidence-based medicine in, 373–381
 - patient choice dynamics in, 380
 - pre-implantation genetic diagnosis and, 336–341
 - risks of add-ons in, 380–381
 - threshold of humanity principle in, 370–372
- researchers ethical capacities, global health emergencies and, 321–322
- research ethics boards (REBs)
 - purpose of, 177–178
 - risk-benefit analysis and, 137–138
- research ethics committees (RECs), 46
 - design and performance criticism of, 180–181
 - fetishisation of consent and, 181–182
 - future directions for, 184–185
 - innovation oversight and, 292–295
 - neuroscience research and, 304

- research ethics committees (RECs) (cont.)
 purpose of, 177–178
 regulatory role of, 178–180
 risk-benefit analysis and, 137–138
 social value and, 52–53
 standardisation of procedures for, 182–184
- Research Involving People Living in Developing Countries: Position Statement and Guidance Notes for Applicants* (Wellcome Trust), 151
- research-therapy divide, continuous learning systems and, 277–286
- Resnik, D. B., 52
- resource/power imbalance, participatory governance and, 126–127
- respect for persons, autonomy guidelines and, 27–29
- responsiveness, in health research governance, 259–260
- review, proportionality of, 39–40
- revisionism, scientific claims and, 49
- Richardson, Megan, 246
- Richert, Lucas, 303–304
- Rid, A., 49–52, 71–72
- The Right to Privacy* (Richardson), 246
- right to try principle
 clinical innovation and, 288–289
 misinformation about reproductive medicine and, 379
- rigorous justification, proportionality and, 43
- Rijke, J., 263
- Riles, Annelise, 284–285
- Rip, A., 159–160
- risk
 defined, 130
 failure in health research and, 158–166
 in health research governance, 259–260
 identification of, 130–132
 institutional aversion to, 211
 medical device classification based on, 279
 re-embedded risk in medical devices, 281–284
 of reproductive add-on treatments, 380–381
 SaMD risk characterization framework, 282–283
 social value of research and, 199–200
- risk-benefit analysis
 benefits identification, 132–134
 disclosure of research findings and, 230–231
 first-order proportionality and, 37–38
 in health research regulation, 130–138
 health research regulation and, 14
 medical devices and, 160–162
 methodologies for, 135–137
 procedural issues, 137–138
 public interest and role of, 250–251
 quantification of, 134–135
 risk identification in, 130–132
- risk object designation
 AI/ML algorithm and, 279–281
 medical device regulation and, 386–389
 re-embedded risk and sociality and, 281–284
 regulatory governance and, 285–286
 software as medical device, 277–278
- Robertson, John, 178
- Roche, Ellen, 21
- Rogers, Wendy A., 13, 17–26
- Rose v. Secretary of State for Health*, 385–386
- Rowe, G., 114
- Royal Academy of Sciences, 218
- Royal Society (UK), 218, 220
- Royal Society of Canada, 219–220
- Rudge, Chris, 287–295
- rules-based approaches (RBAs)
 automated healthcare regulation and, 270–271
 development of, 169–172
 health research regulation and, 167–176
 limitations, 172–173
- R (Source Informatics) v. Department of Health*, 246
- R (W,X,Y and Z) v. Secretary of State for Health (2015)*, 245–246
- safety
 expectations and failure involving, 160–162
 of traditional medicine, research on, 299–301
- Salter, B., 288–289
- Schaefer, Gerald Owen, 13–14
- Schulz, S., 112–113, 117
- science and technology studies (STS)
 health research regulation in, 48–49
 public engagement in, 112–113
 traditional and non-conventional medicines and, 303–304
- scientific truth
 health policy and, 217
 negotiation and agreement over, 49
- scientific uncertainty, risk-benefit analysis and, 134–135
- secondary research
 findings from, 229–230
 institutional decision-making on, 212–213
 regulation of, 199–200
- second-order proportionality, defined, 37–38
- security, data access governance and, 188–189
- self-development, automated healthcare regulation and, 273
- self-narrative, health research participation and, 235–236
- self-regarding attitudes, relational autonomy and, 32
- self-trust, relational autonomy, 32
- semi-autonomous consent, 110
- sequencing, in health research regulation, 395–396
- Serwadda, D., 87–89
- Seth, Nayha, 99–101, 167–176
- Sherkow, Jacob, 141–142
- Shreve, N., 376
- Simm, Kadri, 148–157
- single institutional review board (sIRB), proposals for, 200–201
- situational vulnerability, 33
- slippery slope ideology, human germline research and, 349–350
- social conditions
 adaptive governance and, 262–263
 Big Data research and, 123
 relational autonomy and, 31
- social learning, adaptive governance and, 263–265
- social practices of healing, 299–301

- social value
 application of, 52–55
 automated health regulation and, 270–271
 benefit analysis and, 53–54
 benefit evaluation and, 54
 benefit treatment and, 54
 decision-making and, 54
 of global health emergency research, 317–318
 global health emergency research and, 318–320
 health research regulation and, 14, 46–55, 199–200, 268
 meaning of, 49–51
 proportionality and, 40–41
 re-embedded risk in medical devices and, 281–284
 scholarly debate on, 51–52
 in sociology of science, 47–49
 solidarity as, 58–59
 values and, 49–51, 394–396
- sociology of science
 neuroscience research and, 306–307
 social value in, 47–49
 therapeutic interactions research, 299
- soft law
 on benefit sharing, 152
 genomics research and, 336–341
- software as medical device (SaMD)
 IDx-DR AI diagnostic system, 278–281
 regulation of, 277–278
 risk characterization framework, 282–283
- solidarity
 applicability and adjustments in HHR and, 58–59
 automated health regulation and, 270–271
 as benefit sharing argument, 150–151
 as community and system value, 58–59
 in health research regulation, 14, 56–64
 meaning of, 56–58
 rare diseases and orphan drugs research and, 61–63
- Somatic Gene and Engineered Cell Therapies* (CCA), 219–220
- somatic gene therapy, regulation of, 336–341
- somatic/germline distinction, human germline research and, 350
- Sorauf, F. J., 240
- Sorbie, Annie, 14, 65–72
- Spanish Agency for Medicaments, Argentinian
 collaboration with, 329
- special vulnerability paradigm, 19–20
 health research ethics and, 19–20
- stakeholder engagement
 automated health regulation and, 268–269
 Big Data research and, 257–259
 data protections and, 189
 failure in health research and, 158–159
 independent, interdisciplinary data access and, 193–194
 marginalisation in vaginal mesh failure and, 162–165
 principles-based approaches and, 171–172
 value-driving paradigm for, 394–396
- stare decisis*, institutional decision-making and, 212–213
- Stark, Laura, 178–179
- stem cell research
 Argentinian regulation of, 326–328
 autologous mesenchymal stem cell case, 290–292
 regulation and oversight of, 359–362
 shifting regulatory boundaries in, 362–363
 vulnerability issues in regulation of, 363–364
- Stem Cell Research Oversight (SCRO) committees,
 interspecies research oversight, 360
- stereotyping, in vulnerability research, 20–22
- stewardship
 ethics in health research and, 182–184
 health research regulation and, 268, 397–399
 participatory health research governance and, 124
- Stewart, Cameron, 287–295
- Stilgoe, J., 112
- Stoljar, Natalie, 13, 27–36
- study design and size, RCTs and, 133
- subjectivity, public engagement and, 113–116
- substantial equivalence principle, medical device risk and,
 160–162
- supplementary guidance, health research regulation,
 173–175
- surrogate licensing, patent regulation and, 141–142
- systemic oversight
 AFIRRM model and, 262
 Big Data research and, 259–260
 context in, 262
 structures of governance and, 263
- systems approach
 participatory governance in health research and,
 123–126
 to research regulation, 4–5
- system value, solidarity as, 58–59
- Taylor, Mark, 68–69, 71–72, 239–247
- technology
 Argentinian regulation of, 324–325
 automated healthcare, 266–274
 automated healthcare regulation and, 270–271
 collaborative licensing and, 144–145
 disturbance of regulation from, 382–383
 failure of, 158–166
 health research regulation and, 99–101, 198–199
 informed consent and evolution of, 103–104
 non-exclusive research tool licensing and, 142–143
 patent rights and innovation in, 141
 regulatory lapse and, 167–168
 regulatory responsibility and, 271–274
- Tello, J. E., 123–124
- temporary licensing, for medical devices, 165
- ten Have, H., 91
- Ter Muelen, Ruud, 58–59
- Testlin, Henri, 218
- theory-practice gaps, rule-based and practice-based health
 regulation and, 172–173
- therapeutic misconception, benefit sharing and, 154–156
- third-party risks, identification of, 130–132
- Thompson, J., 127
- threshold of humanity principle
 enhancement innovations and, 383
 human embryo research and, 370–372
- Tietjens, Diana, 31

- tokenism
 public engagement and, 118–119
 resistance to participatory governance and, 125
- Tongan people, cultural protections for, 242n.23
- tools for health research regulation, overview, 99–101
- top-down public engagement, 112
- Townsend, David, 14, 73–80
- Traditional Chinese Medicine (TCM), 299–301, 303–304
- Traditional Herbal Medicine Products (THMPD),
 European Directive on, 297–298
- traditional medicine
 economics of clinical guidelines for, 301–302
 history and evolution of, 296–298
 integration and regulation as subordination, 299–301
 research regulation of, 296–305
 uncertainty of knowledges and practices and, 303–304
- tragedy of the anticommons, 141
- translational value
 benefit treatment and, 54
 hypothesis-driven trials, 54
- transnational dynamics, human germline research and,
 353
- transparency
 in benefit sharing, 153–154
 in collaborative research, 82–83
 data across governance and, 189–190, 192
 informed consent and, 104–105
 proportionality and, 43
 public engagement and, 118–119
- Trudeau, Justin, 216–218, 222–223
- Trump, Donald, 220–223
- trust
 automated health regulation and, 268–269
 in data sharing collaborations, 87–89
 global health emergencies and building of, 319–320
 in global health research, 81–89
 health research regulation and, 9, 222
 in institutions, 86–87
 Learning Health Research Regulation System and,
 394–396
 participatory governance and, 127–129
 risk-benefit analysis and, 134–135
 trustworthiness and, 83–85, 248–249, 254–255
- trustworthiness, public expertise and, 248–249, 254–255
- Trustworthy Institutions in Global Health Research
 Collaborations, 14–15
- Turner, Victor, 278
- Tuskegee syphilis study, 28, 34–35
- UK Biobank, 194–195
- uncertainty
 governance and, 262–263
 in neuroscience research, 310–312
 traditional and non-conventional medicines and,
 303–304
- UN Declaration on Human Cloning, 340–341
- Understanding Patient Data and National Health Service
 England report, 70–71, 394–396
- undue inducement, benefit sharing and, 154–156
- unitary theory, public interest and, 240
- United Kingdom
 data protection law in, 243–245
 duty of confidence and privacy protection in,
 245–246
 evidence-informed health policy in, 216–218
 interspecies biomedical research regulations in,
 362–363
 medical device regulation in, 162–165
 research process simplification and harmonisation and,
 200–201
- United States
 patient and public involvement in health research in,
 122–123, 126
 third-party risk protocols in, 130–132
- Universal Declaration of Human Rights, 74–75
- Universal Declaration on Bioethics and Human Rights
 (UNESCO), 152
- Universal Declaration on the Human Genome and
 Human Rights (UNESCO), 340–341
- universality, of vulnerability, 19
- upper limit on permissible risk, risk-benefit analysis
 guidelines, 137
- vaginal mesh
 expectations and failure involving, 160–162
 gender marginalisation of harm from, 162–165
- validity in health research
 disclosure of findings criteria and, 231, 236–238
 external vs. internal validity, 133
- values
 automated health regulation and, 270–271
 commonly-held value, public interest and, 240–241
 disclosure of research findings based on, 231, 236–238
 learning healthcare systems and, 391–394
 patent regulation and, 140–141
 social value and, 49–51, 394–396
- Valverde, Mariana, 285–286
- van Delden, Johannes JM, 14, 46–55
- van der Graaf, Rieke, 14, 46–55
- van Gannep, Arnold, 278, 389
- van Lente, H., 159–160
- virtuous action, global health emergencies and, 321–322
- voluntariness
 disclosure of research findings criteria based on, 231,
 236–238
 informed consent and, 104–108
 of trust, 84–85
- vulnerability
 ambiguity in HRR and, 19–20
 benefit sharing and, 154–156
 definition and analysis of, 23–24, 90–91
 global health emergency guidelines and, 316–317
 of groups, 93–95
 health research regulation and, 13
 individuals' vulnerability, 92–93
 interspecies biomedical research and realignment of,
 363–364
 labelling approaches to research on, 20–22
 layers of, 396, 23–24
 politics of health research and, 90–98

- power and, 14–15
 in rare disease research, 62
 relational autonomy and, 33–34
 in research ethics guidelines, 17–18
 risk assessment and, 199–200
 taxonomy, 24
 trust and, 83–85
 universal capacity and, 24–25
- Wainwright, Steven, 313
- Waldby, Catherine, 287–295
- Warnock Committee of Inquiry into Human Fertilisation and Embryology, report by, 366–368
- Warren, Mark, 251–252
- Weijer, Charles, 46–47, 96
- welfare state, enforceability of solidarity and, 58–59
- Wellcome Trust
 on benefit sharing, 151
 Blueprint for Dynamic Oversight of Emerging Science and Technologies, 397–399
 public interest and, 68–69
 Understanding Patient Data initiative, 70–71
- Wendler, D., 49–52
- Wenner, Danielle, 51–52
- Wertheimer, A., 52
- Western Herbalism, 299–301
- Whitton, Tess, 239–247
- WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks, 173–175
- Wiersma, Miriam, 287–295
- Wilcox, D., 115–116
- Willis, R., 119–120
- Wilsdon, J., 119–120
- Working Group on Disaster Research Ethics (WGDRE), 317–318
- World Health Organization (WHO)
 bioethics advisory committees and, 221
 CIOMS collaboration with, 46–47, 59–61
 global health emergency guidelines and, 320–322
Good Clinical Practice, 152
 health practices guidelines, 173–175
 health systems framework, 123–124
 traditional medicine and, 296–301
- World Medical Association (WMA), 103–104
- Wright, E. O., 124–125, 127–129
- Wrigley, A., 91, 97
- written assessments, risk-benefit analysis and, 137–138
- Wynne, B., 112–113
- Yishai, Y., 125
- Zhan, Mei, 303–304
- Zhang, John, 346, 353
- Zita West fertility clinic blog, 376–377

